StockNews.AI
SIGA
StockNews.AI
14 hrs

SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

1. SIGA to host conference call on November 6, 2025 for business updates. 2. CEO Diem Nguyen and CFO Daniel Luckshire will lead the call. 3. SIGA focuses on innovative medicines for infectious diseases, specifically orthopoxviruses. 4. TPOXX® is authorized for treatment of smallpox and mpox in multiple regions. 5. Webcast will be available on SIGA's website for stakeholders.

4m saved
Insight
Article

FAQ

Why Neutral?

The announcement doesn't contain substantive news that could affect stock price. Previous updates have resulted in minor fluctuations.

How important is it?

Investors may find value in the business update, but existing product information is already known.

Why Short Term?

Market activity may respond briefly around the update, but long-term effects are uncertain.

Related Companies

VAXXNVAXMRNA
October 30, 2025 07:30 ET  | Source: SIGA Technologies Inc. NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1141989. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com. Contact:Suzanne Harnettsharnett@siga.com

Related News